That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
Toronto Star
· collected 2026-10-08 · by Matthew Perrone The Associated Press
The FDA announced that its safety review of mifepristone, the primary medication used for abortion in the United States, will continue into next year, with a report expected no later than March 2027. Anti-abortion groups have pushed for this reevaluation since President Trump's term, aiming to restrict the drug’s use further. The FDA is using statistical data mining methods from an electronic database to identify any unknown safety concerns related to mifepristone, amidst several ongoing state lawsuits challenging its regulation.
Written locally by qwen2.5:14b on 2026-10-08,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
The Food and Drug Administration (FDA) announced in court filings that it expects to complete its safety review of mifepristone, a key abortion pill, by March 2024. The FDA's reevaluation was prompted by a lawsuit filed by the state of Louisiana challenging mail delivery of mifepristone. The agency plans to compare mifepristone’s safety data with surgical abortions through 10 weeks’ gestation, analyzing side effects from roughly 100,000 women who took the pill. FDA approved mifepristone in 2000 and has since eased restrictions on its use, including allowing mail delivery of the drug in 2023. Abortion opponents criticize the extended timeline for review as they seek to restrict the drug’s availability ahead of the November 2024 midterm elections where abortion access is a significant voter concern.
Written for “FDA Abortion Pill Review” on 2026-10-08,
grounded in this article and the 1 other(s) covering the same event.
Why this leaning score
The model judged this article politically coded and scored it +0.35, but all 2 of its quote(s) are attributed speech - words the article quotes from someone, not the article's own narration, so the score is not published.
Written under an earlier scoring contract, which gave a paragraph
rather than checkable quotes. Re-analysing this article replaces it.
Leaning score withheld for article 64674: attributed speech only · logged 2026-10-08
The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents hoping to see the drug’s use curtailed.
asserted
use → say → opponents
The FDA gave a court-ordered update on its progress in a legal filing late Wednesday, providing the first substantive information about the controversial reevaluation ordered by Health Secretary Robert F. Kennedy Jr.
Mifepristone was first approved by the FDA in 2000.
asserted
Mifepristone → give → 2000
The agency has repeatedly reaffirmed the pill’s safety and effectiveness over the years, in addition to easing a number of restrictions on the drug, including dropping a requirement that it be dispensed in person.
asserted
it → reaffirm → person
But since President Donald Trump returned to the White House, anti-abortion groups and their allies in Congress have pushed the administration to revisit the pill, in the hopes of restricting its use.
asserted
groups → return → use
The FDA said in its filing that it expects to complete a safety study of the pill by mid-December this year.
asserted
it → say → December
A report on the findings is expected “no later than March 2027,” after which the agency will decide whether to impose new restrictions or other changes on the drug’s use.
asserted
agency → expect → use
Gavin Oxley of Americans United for Life, an anti-abortion group, criticized the move as a lack of “true leadership” by Trump administration officials.
asserted
Oxley → criticize → officials
“The administration continues to find itself on the wrong side of women’s health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill,” Oxley said.
asserted
Oxley → continue → pill
The two-drug regimen of mifepristone, combined with a second drug misoprostol, is the most common form of abortion in the U.S.
The FDA was directed to provide the latest update by a federal judge in a case brought by the state of Louisiana alleging that mail-delivery of mifepristone undermines the state’s abortion ban.
asserted
delivery → combine → ban
It’s one of several state lawsuits related to mifepristone winding their way through the courts.
asserted
It → ’ → courts
Last month a three-judge panel for the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana’s case, including whether the state had the legal standing to challenge FDA’s oversight of mifepristone.
asserted
state → question → mifepristone
Any ruling from the 5th Circuit on the Louisiana case would not immediately change the landscape because the Supreme Court has blocked changes to the drug until it sees the case again.
asserted
it → change → case
The FDA said Wednesday it is using a “statistical data mining method” to discover “unknown safety concerns,” that may exist with the drug.
uncertain
that → say → drug
The data comes from an electronic database that collects reports of medical injuries and drug side effects from major health networks and insurers.
asserted
that → come → networks
In addition to the safety study, the agency said it is considering a number of petitions proposing changes to how mifepristone is prescribed and distributed.
asserted
mifepristone → say → changes
Abortion opponents have focused most of their efforts on a 2021 decision allowing doctors to prescribe the drug online and send it through the mail during COVID-19.
asserted
doctors → focus → COVID-19
That decision, made permanent under President Joe Biden in 2023, had the effect of undermining a number of state abortion bans, since women can receive the drug through the mail.
asserted
women → make → mail
The Associated Press’ health and science coverage receives financial support from the AP Fund for Journalism and private foundations.
asserted
coverage → receive → Journalism
The Aporia
